Join Growin Stock Community!

Vtv therapeutics inc.VTVT.US Overview

US StockHealthcare
(No presentation for VTVT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VTVT AI Insights

VTVT Overall Performance

VTVT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VTVT Recent Performance

-7.02%

Vtv therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

VTVT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VTVT Key Information

VTVT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VTVT Profile

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Price of VTVT

VTVT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VTVT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.97
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8839.69
PB Ratio
2.09
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-138058.82%
Revenue Growth (YoY)
-98.30%
Profit Growth (YoY)
-98.30%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.97
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8839.69
PB Ratio
2.09
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-138058.82%
Revenue Growth (YoY)
-98.30%
Profit Growth (YoY)
-98.30%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is VTVT's latest earnings report released?

    The most recent financial report for Vtv therapeutics inc. (VTVT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VTVT's short-term business performance and financial health. For the latest updates on VTVT's earnings releases, visit this page regularly.

  • How much cash does VTVT have?

    At the end of the period, Vtv therapeutics inc. (VTVT) held Total Cash and Cash Equivalents of 98.5M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VTVT's EPS continuing to grow?

    According to the past four quarterly reports, Vtv therapeutics inc. (VTVT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VTVT?

    Vtv therapeutics inc. (VTVT)'s Free Cash Flow (FCF) for the period is -5.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 18.64% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.